802 results about "Prostatic Cancers" patented technology

The composition of the present invention is geared towards treating hyperhidrosis or any condition involving and/or promoting excessive sweating, typically involving the whole body, include hyperthyroidism or similar endocrine disorders; endocrine treatment for prostatic cancer or other types of malignant disorder; severe psychiatric disorders; obesity and menopause. The foamable composition of the present invention is suitable for treating palmar hyperhidrosis; axillary hyperhidrosis; plantar hyperhidrosis; hyperhidrosis of the trunk and/or the thighs; and facial hyperhidrosis; and any combination of them consisting of a therapeutic foamable composition including: an active agent, suitable for the treatment or prevention of hyperhidrosis.

In a method for diagnosis and treatment of a patient with a tumor relating to prostate cancer, the following steps are implemented. A differential diagnosis of prostate cancer versus prostatitis and/or BPH is conducted on a patient using a cost-effective diagnosis method. If prostate cancer is diagnosed in the patient using a cost-effective measurement method, a characteristic value for the tumor aggressiveness of the prostate cancer is determined. A watchful waiting treatment is implemented with the patient given a characteristic value below a predeterminable first limit value. The size and position of the tumor is determined using a cost-effective method given a characteristic value above the first limit value. A cost-effective ultrasonic theranosis or a conventional therapy is conducted for a size below a second predeterminable limit value. The presence of metastases in the patient is checked, with a cost-intensive method generating image information, for a size above the second limit value. A metastasis treatment is implemented in the event that metastases are present. In the event that no metastases are present, a tumor treatment based on the aforementioned image information generated is implemented.

Provided herein are compounds according to Formula I and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancers such as colon, ovarian, pancreatic, breast, liver, prostate and hematologic cancers:

The invention provides for the detection and quantification of PSMA, PSMA', and other prostatic markers in serum samples as well as in other types of samples for use in differentiating prostate cancer, benign prostatic hyperplasia, and negative diagnoses. The diagnostic detection of nucleic acids, such as mRNAs, which encode prostatic markers in cell lysates and other sample sources is also provided. In addition to the multiplexed detection/quantification of these protein- and nucleic acid-based markers, the invention also includes biochips, kits and integrated systems.

The invention provides a human antibody that binds human CSF-1R with high affinity. Antibodies of the present invention have significant advantages over the antibodies known in the art by being multifunctional: inhibiting signaling of CSF-1R, internalizing and inducing CSF-1R degradation and stimulating ADCC in cell including tumors, macrophages and monocytes. They are also shown to be effective in treating leukemia, breast, endometrial and prostate cancer alone or in combination with docetaxel, paclitaxel, Herceptin® or doxorubicin.

The invention provides therapeutic methods for inhibiting, ameliorating or alleviating the hyperproliferative cellular activity of diseases of the prostate, e.g., prostatic cancer and prostatic hyperplasia, which includes administering to a patient in need thereof an active vitamin D analogue and another anticancer agent. Cell differentiation is promoted, induced or enhanced without causing to the patient dose-limiting hypercalcemia and hypercalciuria.

The invention relates to quercetin-3-O-acyl ester and a preparation method thereof and belongs to the technical field of pharmaceutical chemistry. The preparation method comprises the following steps: taking cheap rutin as a starting raw material and preparing a quercetin-3-O-acyl ester compound through benzylation, hydrolysis under the acidic conditions, esterification, catalytic hydrogenolysis and other reactions. The method has the characteristics of good selectivity, mild reaction condition, high yield, low cost, simplicity and convenience in operation, easiness in industrial production and the like. In addition, the inhibitory effect of the obtained quercetin-3-O-acyl ester on human esophageal squamous carcinoma cells EC9706, human prostatic cancer cells PC-3 and human gastric cancer cells MGC-803 is remarkably superior to that of quercetin; and the quercetin-3-O-acyl ester can be used in the field of foods and medicines and is possible to develop into a new candidate drug for treating tumor.

The invention provides brefeldin A ester derivatives having antitumor activity and their preparation method and use. The brefeldin A ester derivatives have structures shown in the structural general formula (I). The brefeldin A ester derivatives have high effects on esophagus cancer, lung cancer, kidney cancer, colorectal cancer and prostatic cancer and have an in-vitro detection effective inhibition rate of 80%. The preparation method of the brefeldin A ester derivatives has simple processes and can be operated easily.

The invention discloses a prostatic cancer computer-assisted detection method and system based on multi-parameter MRI and relates to the field of medical image processing. The method includes the following steps that at a training stage, firstly, a clinical case sample is preprocessed, then a prostate region and a focus candidate region are automatically extracted, and then features of the focus candidate region are calculated and used for training a classifier; at a testing stage, the trained classier is used for classifying the features of the focus candidate region automatically extracted from the tested clinical case sample, and a corresponding diagnosis result is obtained and serves as reference comments to be provided for doctors. A series of quantitative indexes and corresponding malignancy probability values are provided for radiologists, and the doctors can be effectively assisted in diagnosing the prostatic cancer through an MRI image.

The invention relates to nitrogen-atom-containing arteannuin dimers disclosed as Formula (1) and pharmaceutically acceptable salts thereof, wherein X is NR, NR(CH2)nNR or a formula disclosed in the specification; R is H or C14 alkyl group; Y and Z are respectively (CH2)m, (CH2)n(OCH2CH2)m, OC(CH2)nCO or COAr; Ar is phenyl group, naphthyl group or heterocyclic group; N is a 2-8 whole number, and mis a 1-11 whole number; and the heterocyclic group is quinary or sexenary, and contains 1-2 heteroatoms selected from N, O and S. The invention also provides a preparation method of the nitrogen-atom-containing arteannuin dimers, a pharmaceutical composition of the nitrogen-atom-containing arteannuin dimers, and application of the nitrogen-atom-containing arteannuin dimers in preparing drugs for treating cancers, especially endometrial carcinoma, oophoroma, cervical carcinoma, breast cancer, colon cancer, lung cancer, prostatic cancer, liver cancer and/or stomach cancer.

The invention discloses an immune-electrochemical sensor based on an AuNPs@AgNCs nano composite material, construction and applications thereof. Ab1 is fixed by graphene, PSA is taken as the target analyte, SA-AuNPs@AgNCs labeled by streptavidin is easily combined with monoclonal antibody Ab2(biotin-Ab2) which has been modified by biotin, and thus a PSA immunity sensor can be prepared by a sandwich interlaying method through the specific reactions between an antibody and an antigen. When the immune sensor is used, silver and H2O2 are precipitated on the sensor through electric catalytic reduction reactions, the detection is rapid and sensitive, has good specificity, and is capable of detecting the concentration of PSA with an ultralow content. The concentrations of f-PSA and t-PSA in serum of prostatic hyperplasia patients and prostatic cancer patients can also be detected by the sensor, so the sensor has an important meaning for diagnosis and identification on gray areas in prostatic cancer diagnosis.

The invention relates to a new crystal form of a medicament, namely abiraterone acetate for treating prostatic cancer and a preparation method thereof, a pharmaceutical composition containing the new crystal form, and application of the new crystal form in preparing medicines for treating prostatic cancer.

The invention discloses a mytilus edulis enzymolysis polypeptide. The mytilus edulis enzymolysis polypeptide is characterized by containing the following amino acid sequence: Asp Leu Tyr. The mytilus edulis enzymolysis polypeptide is prepared by adopting the following steps of: (1) preparing homogenate from mytilus edulis meat, adding alkaline protease, deactivating the protease, centrifuging, and taking clear solution of the upper layer; (2) performing ultra-filtration on the clear solution, collecting hydrolysate with the molecular weight of below 3K, concentrating, and performing freeze drying; (3) performing chromatographic separation by adopting a DEAE-SepharoseFF ion exchange column; (4) performing chromatographic separation by adopting a Sephadex G-25 gel column; and (5) performing high performance liquid chromatography purification. The invention also discloses application of the mytilus edulis enzymolysis polypeptide prepared by the steps in prostatic cancer resistance. Compared with the prior art, the invention has the advantages that: the mytilus edulis is subjected to enzymolysis and purification by adopting an optimal protease and an optimal technology, a strong cell proliferation inhibiting effect is achieved when the obtained target peptide is applied to prostatic cancer resistant cells, and a feasible research path is provided for resisting prostatic cancer.

The invention discloses attenuated salmonella typhimurium and application of a genetically engineered bacterium of the attenuated salmonella typhimurium in preparation of a medicine for treating the prostatic cancer. The attenuated salmonella typhimurium has a tumor targeting property and an obvious suppression effect on prostate cancer cells, and the genetically engineered bacterium consisting of the attenuated salmonella typhimurium and plasmids also has the tumor targeting property; furthermore, the attenuated salmonella typhimurium with the plasmids cloned with an L-methioninase gene can continuously express L-methioninase in a tumor tissue, and methionine and other nutritional substances are greatly consumed, so that tumor cells are lack of nutrition and grow slowly; therefore, the attenuated salmonella typhimurium can be used for preparing the medicine for treating the prostatic cancer.